All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Praxis Precision Medicines Q3 2026 net loss widens 27% to $94.2 million

By Public Technologies
  • Praxis Precision Medicines’ third-quarter 2026 net loss widened 27% year over year to $94.2 million.
  • General and administrative expenses more than tripled year over year to $42.7 million.
  • Cash, cash equivalents and marketable securities totaled $1.3 billion at September 30, 2026, providing an expected runway into 2028.
  • FDA target action dates remain December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide.
  • Topline results from relutrigine’s EMERALD study in broad developmental and epileptic encephalopathies are expected in the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872955) on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.